Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Eidos Therapeutics Inc. EIDX

Healthcare Biotechnology
"Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins."
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:EIDX)

BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

GlobeNewswire January 26, 2021

Stockholders of BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Approve BridgeBio Pharma, Inc. Acquisition of Eidos Therapeutics, Inc.

GlobeNewswire January 19, 2021

BridgeBio Pharma, Inc. and Eidos Therapeutics, Inc. Announce January 21, 2021 Election Deadline for Merger

GlobeNewswire January 13, 2021

SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

ACCESSWIRE IA January 12, 2021

MERGER INVESTIGATION: Halper Sadeh LLP Investigates CPAH, HMSY, SNSS, EIDX; Shareholders Are Encouraged to Contact the Firm

ACCESSWIRE IA January 8, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds EIDX, IPHI, ALXN, and XLNX Shareholders About Its Ongoing Investigations

PR Newswire January 6, 2021

ALERT: Halper Sadeh LLP Investigates ALXN, SPWH, CBMG, STND, EIDX; Shareholders Are Encouraged to Contact the Firm

PR Newswire January 5, 2021

EIDOS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of EIDX and Encourages Investors to Contact the Firm

GlobeNewswire January 4, 2021

Leading Independent Proxy Advisory Firm ISS Recommends BridgeBio Pharma and Eidos Therapeutics Stockholders Vote "FOR" Proposed Merger

GlobeNewswire January 4, 2021
View More News ››

Opinion & Analysis (NDAQ:EIDX)

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan

Streetwise Reports September 12, 2019
View More Opinion ››

Bullboard Posts (NDAQ:EIDX)

Be the first to post on this bullboard.

Good Natured Products Inc.

Good Natured Products Inc.

good natured Products Inc. offers an assortment of plant-based products made all, or in part, from the maximum possible ...
View More »